VYGR Stock Forecast: Voyager Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Voyager Therapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Voyager Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Momentum (17): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VYGR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VYGR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 17 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 12 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2025 | Wedbush | Maintains | Outperform | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 12 Mar 2025 | Wedbush | Reiterates | Outperform | — |
| 12 Mar 2025 | Wells Fargo | Maintains | Overweight | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Jan 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 Dec 2024 | Citigroup | Initiates | Buy | — |
| 14 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Oct 2024 | Leerink Partners | Initiates | Outperform | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VYGR.
This page is one stock. Monday covers all of them.
VYGR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VYGR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Voyager Therapeutics, Inc. returned −61.3% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VYGR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.8×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 29% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −58.9%
- Return on assets
- −29.4%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Voyager Therapeutics, Inc. has a market value of $94.6M and an enterprise value of $18.3M.
Revenue in the twelve months to 30 June 2026: $34.5M. The latest quarter shrank 39.1% year on year.
Net income over the same four quarters: −$107.7M, a −312.6% net margin.
Diluted earnings per share, trailing twelve months: −$1.81.
Free cash flow in the twelve months to 30 June 2026: −$121.4M.
Voyager Therapeutics, Inc. employs 141 people — $244K of revenue per employee.
Data provided by Twelve Data
VYGR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VYGR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Voyager Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VYGR
What is the VYGR stock price forecast for 2026-2027?
The median 12-month analyst price target for Voyager Therapeutics, Inc. is $12, with estimates ranging from $8 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VYGR stock a buy right now?
Of the 11 analysts covering Voyager Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Voyager Therapeutics, Inc. 61 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VYGR?
As at 18 Nov 2026, Voyager Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
Will VYGR stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts is $12, and Ticker Nerd's factor model ranks Voyager Therapeutics, Inc. 61 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VYGR stock forecast for 2030?
No analyst covering Voyager Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VYGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $25 over the next 12 months.
How has VYGR stock performed over the past year?
Voyager Therapeutics, Inc. returned -61.3% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases. The company’s current programs center on disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and frontotemporal dementia.
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases. The company’s current programs center on disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. Its pipeline includes tau-focused and other neuroscience candidates, while its TRACER platform is designed to support adeno-associated virus-based delivery for targeted therapies. Voyager Therapeutics works at the intersection of genetics, neurology, and drug delivery, aiming to create treatments that address conditions with limited therapeutic options. Founded in 2013 and headquartered in Lexington, Massachusetts, the company plays a specialized role in the biotechnology market through its focus on neurogenetic research and clinical-stage development.
CEO Dr. Alfred W. Sandrock Jr., M.D., Ph.D. · 141 employees · United States · https://www.voyagertherapeutics.com